Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO) is scheduled to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Sangamo Therapeutics to post earnings of ($0.22) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). The company had revenue of $2.04 million for the quarter, compared to analyst estimates of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. On average, analysts expect Sangamo Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.54 on Wednesday. Sangamo Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.67. The company has a market capitalization of $112.03 million, a price-to-earnings ratio of -0.37 and a beta of 1.40. The company has a 50-day simple moving average of $0.68 and a 200 day simple moving average of $0.59.

Analysts Set New Price Targets

Several research firms have recently commented on SGMO. StockNews.com initiated coverage on Sangamo Therapeutics in a research report on Saturday, April 27th. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a report on Thursday, March 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Sangamo Therapeutics presently has an average rating of “Hold” and a consensus price target of $5.67.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.